摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-((2-chloropyridin-4-yl)oxy)-2-iodo-6-methylpyridine | 1117686-42-6

中文名称
——
中文别名
——
英文名称
3-((2-chloropyridin-4-yl)oxy)-2-iodo-6-methylpyridine
英文别名
3-(2-Chloropyridin-4-yl)oxy-2-iodo-6-methyl-pyridine;3-(2-chloropyridin-4-yl)oxy-2-iodo-6-methylpyridine
3-((2-chloropyridin-4-yl)oxy)-2-iodo-6-methylpyridine化学式
CAS
1117686-42-6
化学式
C11H8ClIN2O
mdl
——
分子量
346.555
InChiKey
ZCFHOXDXZOTOJH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    379.9±42.0 °C(Predicted)
  • 密度:
    1.761±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    35
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] HETEROCYCLIC COMPOUNDS, PREPARATION METHODS THEREFOR, AND METHODS OF USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES, LEURS PROCÉDÉS DE PRÉPARATION ET LEURS MÉTHODES D'UTILISATION
    申请人:INVENTISBIO SHANGHAI LTD
    公开号:WO2020258006A1
    公开(公告)日:2020-12-30
    Provided herein are novel heterocyclic compounds, for example, compounds having Formula I. Also provided herein are methods of preparing the compounds and methods of using the same, for example, in inhibiting TGF-beta mediated signaling and/or for treating cancer.
    本文提供了新颖的杂环化合物,例如具有化学式I的化合物。本文还提供了制备这些化合物的方法以及使用它们的方法,例如用于抑制TGF-beta介导的信号传导和/或治疗癌症。
  • Rapid Generation of a High Quality Lead for Transforming Growth Factor-β (TGF-β) Type I Receptor (ALK5)
    作者:Frederick W. Goldberg、Richard A. Ward、Steven J. Powell、Judit É. Debreczeni、Richard A. Norman、Nicola J. Roberts、Allan P. Dishington、Helen J. Gingell、Kate F. Wickson、Andrew L. Roberts
    DOI:10.1021/jm900807w
    日期:2009.12.10
    A novel class of 4-pyridinoxy-2-anilinopyridine-based TGF-beta type I receptor (also known as activin-like kinase 5 or ALK5) inhibitors is reported. The binding mode of this scaffold was successfully predicted by analyzing possible docked binding modes of literature inhibitors and novel synthetic ideas. Compounds such as 19 are potent ALK5 inhibitors with good physicochemical and pharmacokinetic properties and thus represent high quality leads for further optimization.
  • (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER
    申请人:Nexys Therapeutics, Inc.
    公开号:EP3902796A1
    公开(公告)日:2021-11-03
  • HETEROCYCLIC COMPOUNDS, PREPARATION METHODS THEREFOR, AND METHODS OF USES THEREOF
    申请人:INVENTISBIO SHANGHAI LTD.
    公开号:US20210017187A1
    公开(公告)日:2021-01-21
    Provided herein are novel heterocyclic compounds, for example, compounds having Formula I. Also provided herein are methods of preparing the compounds and methods of using the same, for example, in inhibiting TGF-beta mediated signaling and/or for treating cancer.
  • [EN] PYRIDINYIIOXY PYRIDINES AS ALK5 INHIBITORS<br/>[FR] COMPOSÉS CHIMIQUES 1 - 821
    申请人:ASTRAZENECA AB
    公开号:WO2009022171A1
    公开(公告)日:2009-02-19
    The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess ALK5 (TGFβRl) inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti¬ cancer effect in a warm-blooded animal such as man.
查看更多